380 related articles for article (PubMed ID: 18769919)
1. Mesenchymal stem cells for the treatment of refractory pure red cell aplasia after major ABO-incompatible hematopoietic stem cell transplantation.
Fang B; Song Y; Li N; Li J; Han Q; Zhao RC
Ann Hematol; 2009 Mar; 88(3):261-6. PubMed ID: 18769919
[TBL] [Abstract][Full Text] [Related]
2. Pure red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor-derived erythropoiesis after long-term treatment using different therapeutic strategies.
Helbig G; Stella-Holowiecka B; Wojnar J; Krawczyk M; Krzemien S; Wojciechowska-Sadus M; Markiewicz M; Wylezol I; Kopera M; Holowiecki J
Ann Hematol; 2007 Sep; 86(9):677-83. PubMed ID: 17486341
[TBL] [Abstract][Full Text] [Related]
3. Major ABO-incompatible hematopoietic stem cell transplantation: study of post-transplant pure red cell aplasia and endothelial cell chimerism.
Mueller RJ; Stussi G; Odermatt B; Halter J; Schanz U; Seebach JD
Xenotransplantation; 2006 Mar; 13(2):126-32. PubMed ID: 16623806
[TBL] [Abstract][Full Text] [Related]
4. Prolonged red cell aplasia after major ABO-incompatible allogeneic hematopoietic stem cell transplantation: removal of persisting isohemagglutinins with Ig-Therasorb immunoadsorption.
Rabitsch W; Knöbl P; Prinz E; Keil F; Greinix H; Kalhs P; Worel N; Jansen M; Hörl WH; Derfler K
Bone Marrow Transplant; 2003 Nov; 32(10):1015-9. PubMed ID: 14595389
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of pure red cell aplasia with a single dose of rituximab in a child after major ABO incompatible peripheral blood allogeneic stem cell transplantation for acquired aplastic anemia.
Maschan AA; Skorobogatova EV; Balashov DN; Pashanov ED; Trakhtman PE; Schipitzina IP; Skvortsova YV; Rumiantzev AG
Bone Marrow Transplant; 2002 Sep; 30(6):405-7. PubMed ID: 12235527
[TBL] [Abstract][Full Text] [Related]
6. [Pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation].
Huang XJ; Liu DH; Xu LP; Han W; Jiang Q; Chen YH; Zhang YC; Liu KY; Bao L; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Sep; 26(9):548-50. PubMed ID: 16468333
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of pure red cell aplasia with repeated, low doses of rituximab in two patients after ABO-incompatible allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia.
Helbig G; Stella-Holowiecka B; Krawczyk-Kulis M; Wojnar J; Markiewicz M; Wojciechowska-Sadus M; Kopera M; Kruzel T; Najda J; Nowak K; Holowiecki J
Haematologica; 2005 Nov; 90 Suppl():ECR33. PubMed ID: 16266924
[TBL] [Abstract][Full Text] [Related]
8. [Pure red cell aplasia after allogeneic transplantation of ABO incompatible hematopoietic stem cells].
Bullorsky E; Shanley C; Stemmelin G; Ceresetto J; Rabinovich O
Medicina (B Aires); 2002; 62(6):575-7. PubMed ID: 12532694
[TBL] [Abstract][Full Text] [Related]
9. Impact of nonmyeloablative conditioning regimens on the occurrence of pure red cell aplasia after ABO-incompatible allogeneic haematopoietic stem cell transplantation.
Malfuson JV; Amor RB; Bonin P; Rodet M; Boccaccio C; Pautas C; Kuentz M; Cordonnier C; Noizat-Pirenne F; Maury S
Vox Sang; 2007 Jan; 92(1):85-9. PubMed ID: 17181595
[TBL] [Abstract][Full Text] [Related]
10. Impact of ABO-incompatible donor on early and late outcome of hematopoietic stem cell transplantation.
Ozkurt ZN; Yegin ZA; Yenicesu I; Aki SZ; Yagci M; Sucak GT
Transplant Proc; 2009 Nov; 41(9):3851-8. PubMed ID: 19917400
[TBL] [Abstract][Full Text] [Related]
11. Anti-A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO-incompatible allogeneic bone marrow transplantation.
Lee JH; Lee KH; Kim S; Lee JS; Kim SH; Kwon SW; Kim WK
Bone Marrow Transplant; 2000 Jan; 25(2):179-84. PubMed ID: 10673677
[TBL] [Abstract][Full Text] [Related]
12. Impact of ABO incompatibility on allogeneic peripheral blood progenitor cell transplantation after reduced intensity conditioning.
Canals C; Muñiz-Díaz E; Martínez C; Martino R; Moreno I; Ramos A; Arilla M; Boto N; Pastoret C; Remacha A; Sierra J; Madoz P
Transfusion; 2004 Nov; 44(11):1603-11. PubMed ID: 15504166
[TBL] [Abstract][Full Text] [Related]
13. Pre-transplant reduction of isohaemagglutinin titres by donor group plasma infusion does not reduce the incidence of pure red cell aplasia in major ABO-mismatched transplants.
Damodar S; George B; Mammen J; Mathews V; Srivastava A; Chandy M
Bone Marrow Transplant; 2005 Aug; 36(3):233-5. PubMed ID: 15908965
[TBL] [Abstract][Full Text] [Related]
14. Outcomes after major or bidirectional ABO-mismatched allogeneic hematopoietic progenitor cell transplantation after pretransplant isoagglutinin reduction with donor-type secretor plasma with or without plasma exchange.
Curley C; Pillai E; Mudie K; Western R; Hutchins C; Durrant S; Kennedy GA
Transfusion; 2012 Feb; 52(2):291-7. PubMed ID: 21848968
[TBL] [Abstract][Full Text] [Related]
15. Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation.
Griffith LM; McCoy JP; Bolan CD; Stroncek DF; Pickett AC; Linton GF; Lundqvist A; Srinivasan R; Leitman SF; Childs RW
Br J Haematol; 2005 Mar; 128(5):668-75. PubMed ID: 15725089
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and long-term outcome of treatment for pure red cell aplasia after allogeneic stem cell transplantation from major ABO-incompatible donors.
Hirokawa M; Fukuda T; Ohashi K; Hidaka M; Ichinohe T; Iwato K; Kanamori H; Murata M; Sakura T; Imamura M; Adachi S; Suzuki R; Morishima Y; Sakamaki H;
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1026-32. PubMed ID: 23583828
[TBL] [Abstract][Full Text] [Related]
17. [Pure red cell aplasia following ABO-incompatible allogeneic hematopoietic stem cell transplantation].
Fan H; Jing Y; Li HH; Lu XC; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):364-7. PubMed ID: 18426666
[TBL] [Abstract][Full Text] [Related]
18. Prolonged isolated red blood cell transfusion requirement after allogeneic blood stem cell transplantation: identification of patients at risk.
Dahl D; Hahn A; Koenecke C; Heuft HG; Dammann E; Stadler M; Buchholz S; Krauter J; Eder M; Sykora KW; Klein C; Ganser A; Sauer M
Transfusion; 2010 Mar; 50(3):649-55. PubMed ID: 19929861
[TBL] [Abstract][Full Text] [Related]
19. Treatment of resistant pure red cell aplasia after major ABO-incompatible bone marrow transplantation with human adipose tissue-derived mesenchymal stem cells.
Fang B; Song Y; Zhao RC; Han Q; Cao Y
Am J Hematol; 2007 Aug; 82(8):772-3. PubMed ID: 17573692
[No Abstract] [Full Text] [Related]
20. Safety and impact of donor-type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch.
Scholl S; Klink A; Mügge LO; Schilling K; Höffken K; Sayer HG
Transfusion; 2005 Oct; 45(10):1676-83. PubMed ID: 16181220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
